Bracco Diagnostics

January 6, 2012 - Bracco Imaging SpA has acquired Swiss Medical Care (SMC), a Swiss company headquartered in Lausanne and engaged in research, production and marketing of automated systems for the administration of contrast agents for diagnostic imaging.

The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals to stop using CardioGen-82 for cardiac positron emission tomography (PET) scans. The manufacturer, Bracco Diagnostics Inc., has decided to voluntarily recall CardioGen-82 this week after two patients set off radiation detectors at a U.S. border crossings due to strontium contamination.

December 16, 2010 – Bracco Imaging demonstrated how its customized evidence-based diagnostic imaging solutions are meeting the demands of an evolving radiology market at the Radiological Society of North America (RSNA) meeting.

October 19, 2010 — CardioGen-82 (Rubidium Rb 82 Generator) when used with positron emission tomography (PET) myocardial perfusion imaging (MPI) has been shown to produce “reasonably low radiation exposure” of 3.7mSv for a complete rest/stress study. 1

Automated contrast media injectors are used in cardiac imaging to help improve patient safety and enhance image quality. These devices can control contrast dosage, record the amount used, speed injections to keep up with faster computed tomography (CT) scanners, and warn clinicians of potential hazards, such as air embolisms or extravasations.